Telehealth Is Fastest Growing Segment Fueling The Growth Of Oncology Radiopharmaceuticals Market
Oncology Radiopharmaceuticals Market |
The global Oncology Radiopharmaceuticals Market is estimated to be valued at US$ 7351 Mn in 2023 and is expected to exhibit a CAGR of 45.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Oncology radiopharmaceuticals refer to a group of drugs which are used for both
diagnostic as well as therapeutic purposes in cancer treatment. They contain
radioactive isotopes which enable the visualization and treatment of cancer
tissues. These drugs aid in detecting the specific locations of tumors and also
help eliminate cancer cells with targeted radiation therapy. Approval of new
radiopharmaceuticals, increasing prevalence of cancer and rising awareness
regarding early diagnosis are driving the growth of this market.
Market key trends:
One of the key trends witnessed in the market currently is the rise in use of
theragnostic radiopharmaceuticals. Theragnostics combines therapeutics and
diagnostics into a single drug which allows personalizing treatments for
patients. These radiopharmaceuticals help improve clinical outcomes by allowing
providers to accurately diagnose the disease and simultaneously treat it with
personalized radiation therapy. Research is ongoing to develop advanced
theragnostic agents with improved tumor targeting ability and reduced side
effects. Development of such innovative radiopharmaceuticals will strengthen
personalized cancer care in the coming years.
Segment
Analysis
The oncology radiopharmaceuticals
market is segmented by product type, application, end user and region. By product
type, the lutetium-177 segment is dominating the market and is projected to
grow at the highest CAGR during the forecast period. Lutetium-177 has superior
atomic and nuclear properties for targeted radionuclide therapy of cancer. It
has a therapeutic ratio that makes it well suited for radiotherapy applications
with good tumor targeting and dose delivery.
Key Takeaways
Global
Oncology Radiopharmaceuticals Market Demand is expected to witness high
growth, exhibiting a CAGR of 45%
over the forecast period, due to increasing incidences of cancer worldwide.
Regional analysis - North America dominated the market in 2023 and is expected
to continue its dominance over the forecast period. This is attributed to
growing adoption of nuclear medicine procedures and availability of advanced
diagnostic technologies in the region. Asia Pacific is expected to be the
fastest growing region during the forecast period owing to large patient pool
and rising healthcare expenditure in the region.
Key players - Key players operating in the oncology radiopharmaceuticals market
are Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus
Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert &
Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant
Pharma Limited, and Cardinal Health.
Comments
Post a Comment